NextCell’s CSO elected to ISCT European Regional Secretary

NextCell Pharma AB’s ("NextCell" or the "Company") CSO, Lindsay Davies, has been officially elected to the position of European Regional Secretary for the International Society for Cell and Gene Therapy.

The International Society of Cell and Gene Therapy is the global leader in pre-clinical and translational cell and gene therapeutics. Dr Davies received notification from ISCT’s President Elect, Chair of the Nominations Committee and CEO, that she had been formally elected to the role of European Regional Secretary by ISCT´s membership.

Dr Davies said, “I am delighted to receive this recognition and have the opportunity to contribute to ISCT´s next chapter and future development.”

Dr Davies will represent NextCell and Sweden for a three year term, in the European Executive Committee, a group of five elected individuals who have been selected as worldclass representatives for European CGT. “I have been an active member of the ISCT for over 10 years, with membership in the Commercialization and Process Development Committees and Particulate Working Group, representing NextCell. I am also a mentor for the ISCT´s early-stage professionals. It will be great to contribute further and give back to a Society that I have bene fitted so much from during my career.”

She continues, “I was asked by ISCT what would be at the forefront of my personal agenda for Europe´s advanced therapies forum. I replied that as an academic who transitioned to industry after many years, I would like to see greater support for academics and start-ups inside Europe to navigate the valley of death for translating their ideas to a clinical product. I would also like to make science accessible to everyone. One of the central limiting factors with cell and gene therapy development is acceptance. While we, as therapy developers, may strive to innovate and develop new medicines, if the patient doesn’t understand or is fearful of such “futuristic” therapies, there is no place for commercialization or widespread usage. Working with NextCell has shown me that irrespective of the stage of development of a new drug product, communicating science to our patients, the public, is integral to our own success.”

Dr Davies will formally commence her new role in June 2023. Further information can be read on ISCT´s webpage https://www.isctglobal.org/membership/elections

‍

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO
Patrik Fagerholm, CFO

Tel:08-735 5595
E-mail: info@nextcellpharma.com
Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

About NextCell Pharma AB

NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study.  ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5%of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).

‍